Trial Profile
A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TRIBE
- 20 Jan 2024 Results of pooled analysis from TRIBE , FIRE-3 and MAVERICC ; investigating the effect of myostatin/activin pathway gene expression and SNPs in mCRC patients, presented at the 2024 Gastrointestinal Cancers Symposium
- 06 Jun 2023 Results assessing the effect of genetic variants in MHC class I and II pathways on first-line treatment outcome in mCRC patients presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 13 Sep 2022 Results of pooled analysis of two studies (TRIBE & TRIBE 2) assessing primary tumor resection in metastatic colorectal cancer patients, presented at the 47th European Society for Medical Oncology Congress.